Fischer Medical Ventures Limited (Fischer MV) is leading a paradigm shift in the healthcare sector by pioneering cutting-edge, cost-effective medical imaging technologies and state-of- the-artdiagnostic innovations on a global scale.
Headquartered in Chennai, India, with a manufacturing facility inthe Andhra Pradesh MedTech Zone (AMTZ) in Visakhapatnam,Fischer MV is spearheading as the first Indian company toindigenously manufacture advanced magnetic resonance imaging (MRI) systems in India, marking a significant milestone in the development of advanced medical imaging solutions within the nation.
From December 2023, Fischer MV has been actively trading on theBombay Stock Exchange (BSE |FISCHER | 524743 | INE771F01025) to propel its journey towards industry leadership in medical imaging and MedTech. The Company envision to be the leading partner for healthcare providers worldwide, specializing in producing cost-effective, high-qualitymedical imaging devices, and offer revolutionary diagnostic solutions with cutting- edge AI platform.
Underscoring the company’s dedication to innovation, adaptabilityand empowering healthcare providers with essential tools for precise diagnoses, Fischer MV strategically expanded into the broader realm of MedTech through targeted investments and acquisitions, consolidating a spectrum of radiology services and diverse portfolio of diagnostic solutions, including, but not limitedto:
▪ Wonder Tech, pioneered the mental health industry with its breakthrough biomarker technology that can significantlyimprove access to quality mental health diagnostics. With just a 60-second voice sample regardless of language, the mental health analysis of a user can be determined by its proprietary AI-driven acoustic-based technology instantly, enabling affordable mentalhealth screening via voice biomarkers, increasing the likelihoodof prevention and early treatment.
▪ Therapy Platform, a technological company committed toenhance the quality of psychological counselling services, aimingto alleviate users’ psychological distress, reduce mental healthcare costs, and mitigate socio-economic burdens. Therapy Platform integrates AI technology into their services to enhance effectiveness, efficiency and developed various AI-empowered products to bolster therapy outcomes and minimize overall costs.
▪ Nervotec, empowers predictive healthcare via its contactless solution without wearables. Users simply look at their owncamera-enabled device and within minutes, Nervotec’s app usingremote photoplethysmography (rPPG) technology and artificialintelligence algorithms will analyse numerous vital signs, andalso can give first-in-the-world haemoglobin measurement (to measure Anaemia and detect Thalassemia) and HbA1C (average glucose level over a period) measurements without requiring vials of blood, totally non-invasive and contactless.
▪ BluSim, a health-tech company dedicated to transform the elder care industry. Using Ballistocardiography technology, a non-invasive method based on the measurement of the body motiongenerated by the ejection of the blood at each cardiac cycle andpowered by advanced algorithms and AI, their “BluSim Mat” converts micro vibrations into meaningful biomarkers, to provide real-time and continuous monitoring of patients’ vitals and detectearly warning for potential health issues.
In a short span of time, Fischer MV has accomplished severalmarket/commercial breakthroughs, including but not limited to:
▪ Collaboration with Tech Avant-Garde (TAG), India’s largest solution provider in the education segment that offers a range of programs designed to enhance digital literacy, skill development, financial digital literacy, and health awareness among students.TAG partners with Fischer MV to incorporate healthcare into their programs, to benefit millions of students and their connected communities. Fischer MV-TAG collaboration in India will start with screening students through Fischer MV’s e-Health Kiosk, a health screening machine that conducts comprehensive diagnostics that will include eye health, audiology, oral health, mental health, lung & respiratory health checks that will be conducted at least 4 times per year for each student. This program is intended to also include parents, teachers, and school communities to achieve the combined mission to foster a healthyconnected learning community.
▪ Entry into Philippines with RiteMED by United Laboratories Inc (Unilab), the leading pharmaceutical company in Philippines. Through DigiHealth Specialists Inc. a wholly owned subsidiary company of Fischer MV, theiradvanced e-Health Kiosk will be introduced to RiteMED pharmacies across Philippines, supported by real-time analyticsand electronic health records. On a national level, the Company targets to sell at least 10,000 units of their e-Health Kiosk to reach out to target population, especially the geographicallyisolated and disadvantaged communities, in support of theUniversal Health Care that is being implemented in the Philippines.
▪ Partnering DoctorOnCall (DOC) platform from Health Digital Technologies, to offer a comprehensive healthcareecosystem, seamlessly merging teleconsultations, onlinepharmacy services, a dynamic health services marketplace,cutting-edge insurance solutions, and bespoke corporate medicalconcierge services. With a robust infrastructure encompassing more than 500 GP clinics network, engaging over 1.9 million registered users, and supporting more than 20 million annual visits, Fischer MV will enter Malaysia healthcare ecosystem with DOC to bring in its wide range of innovative healthcaresolutions, at the same time adopt DOC’s tele medicine platform to other countries where required.
Furthermore, Fischer MV is also relentless in discoveringrevolutionary healthcare technologies in the space of preventive healthcare and have sealed various partnerships to expand themglobally. This includes, but not limited to:
▪ Nanyang Biologics (NYB), a disruptive drug discovery AI platform employing advanced Metagenomics and Metaproteomics Analysis, and successfully unveil the therapeuticpower hidden in various plants. NYB’s innovative Chemical Fingerprinting techniques elucidate molecular structures and optimize identification of potent active ingredients. Further powered by its AI-driven Virtual Screening Platform, NYB could swiftly identify promising drug candidates, reducing discoverylead time and costs substantially. To date, NYB has successfully identified 2 cancer drug candidates ready to start clinical trials and has developed 4 nutraceutical products ready for Fischer MV to help commercialize worldwide.
▪ Bio Angle Vacs Sdn Bhd’s (BAV), a revolutionary animal vaccination/ food security company that leverages advanced recombinant technology and intranasal administration to elicitboth mucosal and systemic immune responses, demonstratingenhanced protection for small ruminants, especially goats and sheep, against bacterial infections with high mortality rates. Their fish and shrimp vaccine products provide cross-protection againsta range of pathogenic diseases prevalent in Asian marine fishcultures, freshwater fish cultures and shrimps. While the company have secured a total of USD 83 million annual sales contracts to date, Fischer MV’s strong sales & partner network will propel BAV’s products globally to benefit farmers andcontribute to food security through enhanced animal healthcare.
Fischer MV has demonstrated its overarching mission in comprehensively addressing all aspects of medical technology and the healthcare sector, spanning cutting-edge imaging devices torevolutionary diagnostics and preventive medicine. Leveraging theirdeep expertise, robust resources, and strategic partnerships worldwide, Fischer MV aims to drive forward progress, enhanceaccessibility, and promote affordability in global healthcare delivery.
Know more about us at: fischermv.com
